Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ContextLogic Inc. - Class A Common Stock (NQ:LOGC)

6.770 +0.030 (+0.44%)
Streaming Delayed Price Updated: 11:34 AM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ContextLogic Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
ContextLogic Slips Aftermarket On Q4 Earnings Miss: Retail’s Cautious
Sentiment on Stocktwits ended ‘neutral’ on Wednesday compared to ‘bearish’ a day ago. 
Via Stocktwits
ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results
From ContextLogic Inc.
Via GlobeNewswire
ContextLogic to Announce Fourth Quarter and Full Year 2024 Results and Provide Strategic Update on March 12, 2025
From ContextLogic Inc.
Via GlobeNewswire
ContextLogic Stock Sees Retail Chatter Spike On BC Partners' Investment Ahead Of Q4 Results
Under the deal, BC Partners planned to buy up to $150 million of convertible preferred units, a newly-formed Delaware limited liability company and a wholly-owned subsidiary of the company. 
Via Stocktwits
Looking Into LogicBio Therapeutics's Recent Short Interest
LogicBio Therapeutics's (NASDAQ:LOGC) short percent of float has fallen 62.5% since its last report. The company recently reported that it has 29 thousand shares sold short, which is 0.12% of all... 
Via Benzinga
Earnings Scheduled For March 12, 2025
Via Benzinga
ContextLogic And BC Partners Forge $150 Million Strategic Partnership For Growth
BC Partners invests $150M in ContextLogic, providing access to $300M in capital. New board members to maximize shareholder value and drive growth. 
Via Benzinga
ContextLogic Announces Up to $150 Million Strategic Investment by BC Partners
From ContextLogic Inc.
Via GlobeNewswire
ContextLogic Inc. Reports Third-Quarter 2024 Financial Results
From ContextLogic Inc.
Via GlobeNewswire
LOGC Stock Earnings: ContextLogic Misses EPS, Beats Revenue for Q2 2024
LOGC stock results show that ContextLogic missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
ContextLogic Inc. Reports Second-Quarter Financial Results
From ContextLogic Inc.
Via GlobeNewswire
11 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC),
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC), Coffee Holding Co., Inc. (Nasdaq – JVA)
From Brodsky & Smith LLC
Via GlobeNewswire
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) CarLotz, Inc. (Nasdaq – LOTZ), LogicBio Therapeutics, Inc. (Nasdaq – LOGC), O2Micro International Limited (Nasdaq – OIIM), Coffee Holding Co., Inc. (Nasdaq – JVA)
From Brodsky & Smith LLC
Via GlobeNewswire
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
From Kahn Swick & Foti, LLC
Via Business Wire
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
Nasdaq Jumps 270 Points; Silver Surges Over 8%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 270 points on Monday. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) LogicBio Therapeutics, Inc. (Nasdaq – LOGC), O2Micro International Limited (Nasdaq – OIIM), Coffee Holding Co., Inc. (Nasdaq – JVA), BTRS Holdings Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. 
Via Benzinga
S&P 500 Surges 2%; Crude Oil Rises Sharply
U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 600 points on Monday. 
Via Benzinga
GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week
Investors are still interested in short squeeze stocks lately and we've got them covered with the ones to watch this week! 
Via InvestorPlace
Blue Apron (APRN) Stock Falls 33% on CFO Departure, Stock Sale
Blue Apron (APRN) stock is sliding lower on Monday as investors react to its CFO leaving the company and plans for a stock sale. 
Via InvestorPlace
Why Is LogicBio (LOGC) Stock Up 600% Today?
LogicBio (LOGC) stock is seeing massive gains on Monday following news that AstraZeneca (AZN) subsidiary Alexion is acquiring the company. 
Via InvestorPlace
LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers LogicBio Therapeutics (NASDAQ:LOGC) shares moved upwards by 641.3% to $2.02 during Monday's pre-market session. The company's market cap stands at $66.5 million. 
Via Benzinga
Why LogicBio Therapeutics Stock Is Soaring Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN) subsidiary Alexion for $2.07 per share.  
Via Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.